Literature DB >> 25389924

Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.

Iris H Wei1, Charles M Harmon, Massimo Arcerito, Debbie F Cheng, Rebecca M Minter, Diane M Simeone.   

Abstract

OBJECTIVE: Patients with nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) have poorer survival than those with functional PNETs. Our objective was to identify risk factors for recurrence after resection to better define surveillance parameters to improve long-term outcomes.
METHODS: A retrospective analysis was performed for NF-PNET patients who underwent resection at the University of Michigan from 1995 to 2012. Immunohistochemical staining of tissues from patients with and without disease recurrence was performed for Ki-67 and the macrophage marker CD68, as tumor-associated macrophages are important for PNET development and progression. Clinicopathological factors and patient outcomes were measured.
RESULTS: Ninety-seven NF-PNET patients underwent surgical resection. There was a recurrence rate of 14.4% (14/97). The median time to recurrence was 0.61 years, with 10 (71%) patients recurring within the first 2 years. Six of 7 patients (86%) monitored at 6-month surveillance intervals were diagnosed with recurrence on their first computed tomographic scan or during the intervening intervals. By Cox proportional hazards analysis, the most significant independent risk factors for recurrence were higher grade, stage, and intraoperative blood loss. High CD68 score and Ki-67 index correlated with recurrence risk, and Ki-67 index inversely correlated with time to recurrence. In patients who otherwise had few risk factors, a high CD68 score was a significant prognostic factor for recurrence.
CONCLUSIONS: In patients with NF-PNETs, risk factors associated with recurrence were high EBL, grade, stage, CD68 score, and Ki-67 index. The CD68 score was an important prognostic factor in patients who otherwise had few clinicopathological risk factors; therefore, the CD68 score should be considered when planning surveillance strategies. We recommend that NF-PNET patients at high risk of recurrence undergo initial surveillance every 3 months for 2 years after surgery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25389924      PMCID: PMC4312612          DOI: 10.1097/SLA.0000000000000262

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  50 in total

1.  Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.

Authors:  Alex B Haynes; Vikram Deshpande; Thun Ingkakul; Parsia A Vagefi; Jackie Szymonifka; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  Arch Surg       Date:  2011-05

2.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

3.  Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients.

Authors:  Jan Franko; Wentao Feng; Linwah Yip; Elizabeth Genovese; A James Moser
Journal:  J Gastrointest Surg       Date:  2009-12-09       Impact factor: 3.452

4.  Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development.

Authors:  S M Pyonteck; B B Gadea; H-W Wang; V Gocheva; K E Hunter; L H Tang; J A Joyce
Journal:  Oncogene       Date:  2011-08-08       Impact factor: 9.867

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.

Authors:  R Bettini; L Boninsegna; W Mantovani; P Capelli; C Bassi; P Pederzoli; G F Delle Fave; F Panzuto; A Scarpa; M Falconi
Journal:  Ann Oncol       Date:  2008-01-21       Impact factor: 32.976

8.  Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study.

Authors:  Lucio Gullo; Marina Migliori; Massimo Falconi; Paolo Pederzoli; Rossella Bettini; Riccardo Casadei; Gianfranco Delle Fave; Vito D Corleto; Claudio Ceccarelli; Donatella Santini; Paola Tomassetti
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

9.  Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer.

Authors:  Michael G House; John L Cameron; Keith D Lillemoe; Richard D Schulick; Michael A Choti; Donna E Hansel; Ralph H Hruban; Anirban Maitra; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-01       Impact factor: 3.267

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  27 in total

1.  Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.

Authors:  Jian-Qiang Lu; Benjamin Adam; Andrew S Jack; Anna Lam; Robert W Broad; Constance L Chik
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

2.  Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).

Authors:  Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

Review 3.  Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.

Authors:  Kristen B Long; Arthur I Collier; Gregory L Beatty
Journal:  Mol Immunol       Date:  2017-12-19       Impact factor: 4.407

Review 4.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

Review 5.  Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.

Authors:  Umar Mehraj; Hina Qayoom; Manzoor A Mir
Journal:  Breast Cancer       Date:  2021-03-04       Impact factor: 4.239

Review 6.  The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Shuaishuai Xu; Chanqi Ye; Ruyin Chen; Qiong Li; Jian Ruan
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 7.  Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Authors:  S M Sadowski; C R C Pieterman; N D Perrier; F Triponez; G D Valk
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

8.  From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors.

Authors:  Miaoyan Wei; Jin Xu; Jie Hua; Qingcai Meng; Chen Liang; Jiang Liu; Bo Zhang; Wei Wang; Xianjun Yu; Si Shi
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

9.  Risk factors for aggressive nonfunctional pancreatic neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspiration.

Authors:  Alexander R Ende; Alireza Sedarat; Pari Shah; Nirag Jhala; Douglas L Fraker; Jeffrey A Drebin; David C Metz; Michael L Kochman
Journal:  Endosc Ultrasound       Date:  2016 Jan-Feb       Impact factor: 5.628

10.  Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors.

Authors:  Shreya Mehta; Philip R de Reuver; Preetjote Gill; Juliana Andrici; Lisa D'Urso; Anubhav Mittal; Nick Pavlakis; Stephen Clarke; Jaswinder S Samra; Anthony J Gill
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.